Detecting primary aldosteronism in Australian primary care: a prospective study

Current guidelines suggest that primary aldosteronism may be underdiagnosed in newly diagnosed hypertension cases. Prior research has shown that general practitioners often overlook secondary causes of hypertension. No prior work had resolved whether screening in primary care could detect PA effectively. This gap motivated a study to evaluate the role of general practitioners in identifying PA. The study aimed to assess whether primary care screening could identify PA in treatment-naïve patients. It was already known that PA is a treatable cause of secondary hypertension. However, the exact prevalence in newly diagnosed patients remained unclear. This study sought to address that uncertainty.

The study aimed to determine the prevalence of primary aldosteronism among newly diagnosed hypertensive patients in primary care. It focused on whether general practitioners could identify PA through aldosterone-to-renin ratio screening. The researchers proposed that early detection in primary care could improve patient outcomes. They wanted to test if a two-step screening process was feasible in this setting. The study also aimed to compare baseline characteristics of those with and without PA. The motivation stemmed from the lack of data on PA detection in primary care settings. The goal was to assess the potential role of GPs in diagnosing this condition. This approach could inform future hypertension management guidelines.

The study used a prospective design across multiple general practices in Victoria, Australia. Participants were adults with newly diagnosed hypertension and no antihypertensive medications. Screening involved measuring the aldosterone-to-renin ratio (ARR) in blood samples. Those with elevated ARR values underwent further testing at a specialized endocrine clinic. Saline suppression testing was used to confirm PA diagnoses. The study collected baseline data on age, sex, blood pressure, and potassium levels. Researchers compared these characteristics between confirmed PA and non-PA groups. The study period spanned from 2017 to 2020 to ensure a representative sample.

Out of 247 screened participants, 62 had elevated ARR values (25%). Saline suppression testing confirmed PA in 35 of these (14%). The confidence interval for this proportion ranged from 10% to 19%. Baseline characteristics like age, sex, blood pressure, and potassium levels were similar across groups. No significant differences were found in these metrics between PA and non-PA patients. The study found that GPs could identify PA through initial ARR screening. The results suggest that primary care screening may detect a notable proportion of PA cases. These findings support the feasibility of a two-step diagnostic approach in primary care.

The study found that 14% of newly diagnosed hypertensive patients had confirmed PA after screening. This suggests that primary care screening may detect a significant number of PA cases. The authors propose that general practitioners could play a role in early PA detection. The results indicate that a two-step screening process is feasible in primary care settings. The study supports further research into the implementation of PA screening protocols. No prior work had resolved the exact prevalence of PA in this population. The findings may inform future guidelines for hypertension management. The authors suggest that early detection could improve treatment outcomes for PA patients.